October 5th 2020
BioPark
Bone Therapeutics grants exclusive license to Link Health and Pregene for the development and commercialization of ALLOB in Greater China and a number of other major Asian countries. Terms include €55 million in total upfront and milestone payments with €10 million expected in next 24 months as well as tiered double-digit royalties on net sales. Please discorver the press relaese here.